The liver disease diagnostics spinout has secured the first tranche of a $10m series A investment by Fosun Pharma initially announced in October 2018.
Glycotest, a US-based liver disease diagnostics spinout of Baruch S. Blumberg Institute and Drexel University, received an initial $3m tranche from its up to $10m series A agreement with drug firm Fosun Pharma on Thursday. Fosun Pharma’s investment was first announced in October 2018 and would result in the corporate taking 40% interest if fully…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
